VIVORYON news, videos and press releases
For more news please use our advanced search feature.
VIVORYON - More news...
VIVORYON - More news...
- Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
- Vivoryon Therapeutics N.V. Announces Changes to Board Composition
- Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
- Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
- Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
- Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
- Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
- Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
- Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
- Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation
- Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board
- Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023
- Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
- Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
- Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
- Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
- Vivoryon Therapeutics N.V. Announces CEO Transition Plan
- Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
- Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million
- Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering
- Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023
- Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023
- Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
- Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
- Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023
- Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease
